RAD51C

Summary

RAD51C (RAD51 paralog C, HGNC:9820) is a protein-coding gene on chromosome 17q22, encoding DNA repair protein RAD51 homolog 3 (O43502). Essential for the homologous recombination (HR) pathway of DNA repair. It is a selective cancer dependency (DepMap: 82.8% of cell lines) and haploinsufficient (ClinGen: sufficient evidence).

This gene is a member of the RAD51 family. RAD51 family members are highly similar to bacterial RecA and Saccharomyces cerevisiae Rad51 and are known to be involved in the homologous recombination and repair of DNA. This protein can interact with other RAD51 paralogs and is reported to be important for Holliday junction resolution. Mutations in this gene are associated with Fanconi anemia-like syndrome. This gene is one of four localized to a region of chromosome 17q23 where amplification occurs frequently in breast tumors. Overexpression of the four genes during amplification has been observed and suggests a possible role in tumor progression. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 5889 — RefSeq curated summary.

At a glance

• Gene–disease (curated): RAD51C-related cancer predisposition (Definitive, ClinGen) — +4 more curated relationships
• GWAS associations: 4
• Clinical variants (ClinVar): 2,222 total — 203 pathogenic, 97 likely-pathogenic
• Phenotypes (HPO): 131
• Cancer dependency (DepMap): dependent in 82.8% of screened cell lines
• Dosage sensitivity (ClinGen): haploinsufficiency sufficient evidence, triplosensitivity no evidence
• MANE Select transcript: NM_058216

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9820
Approved symbol	RAD51C
Name	RAD51 paralog C
Location	17q22
Locus type	gene with protein product
Status	Approved
Aliases	RAD51L2, FANCO
Ensembl gene	ENSG00000108384
Ensembl biotype	protein_coding
OMIM	602774
Entrez	5889

Gene structure

Transcript identifiers

Ensembl transcripts: 42 — 15 protein_coding, 12 nonsense_mediated_decay, 10 retained_intron, 5 protein_coding_CDS_not_defined

ENST00000337432, ENST00000413590, ENST00000421782, ENST00000425173, ENST00000461271, ENST00000461706, ENST00000475762, ENST00000476741, ENST00000482007, ENST00000486827, ENST00000487525, ENST00000487921, ENST00000578151, ENST00000581221, ENST00000583539, ENST00000584617, ENST00000584804, ENST00000622327, ENST00000697675, ENST00000697676, ENST00000697677, ENST00000697678, ENST00000697679, ENST00000697680, ENST00000697681, ENST00000697683, ENST00000697684, ENST00000697685, ENST00000697686, ENST00000697687, ENST00000697688, ENST00000697689, ENST00000697690, ENST00000697691, ENST00000697692, ENST00000697693, ENST00000697694, ENST00000697695, ENST00000875229, ENST00000930423, ENST00000930424, ENST00000948099

RefSeq mRNA: 2 — MANE Select: NM_058216 NM_002876, NM_058216

CCDS: CCDS11611, CCDS45745

Canonical transcript exons

ENST00000337432 — 9 exons

Exon	Start	End
ENSE00003481223	58696693	58696859
ENSE00003481979	58703196	58703329
ENSE00003490455	58720746	58720812
ENSE00003517466	58724040	58724100
ENSE00003547500	58709859	58709990
ENSE00003602501	58694931	58695189
ENSE00003971409	58732484	58732544
ENSE00003971423	58734118	58735611
ENSE00003971431	58692602	58692788

Expression profiles

Bgee: expression breadth ubiquitous, 281 present calls, max score 93.65.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 26.7819 / max 376.7165, expressed in 1803 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161931	23.7814	1801
161932	2.8342	921
161933	0.1663	80

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.65	gold quality
right testis	UBERON:0004534	93.59	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	93.50	gold quality
left testis	UBERON:0004533	93.50	gold quality
testis	UBERON:0000473	93.14	gold quality
right frontal lobe	UBERON:0002810	91.99	gold quality
ventricular zone	UBERON:0003053	91.94	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.43	gold quality
cortical plate	UBERON:0005343	91.40	gold quality
oocyte	CL:0000023	91.37	gold quality
prefrontal cortex	UBERON:0000451	91.35	gold quality
right atrium auricular region	UBERON:0006631	91.18	gold quality
heart left ventricle	UBERON:0002084	90.76	gold quality
ganglionic eminence	UBERON:0004023	90.61	gold quality
cardiac ventricle	UBERON:0002082	90.50	gold quality
right adrenal gland	UBERON:0001233	90.33	gold quality
cardiac atrium	UBERON:0002081	90.23	gold quality
popliteal artery	UBERON:0002250	90.19	gold quality
tibial artery	UBERON:0007610	90.19	gold quality
heart	UBERON:0000948	90.08	gold quality
right adrenal gland cortex	UBERON:0035827	90.08	gold quality
left adrenal gland cortex	UBERON:0035825	90.01	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	89.99	gold quality
cingulate cortex	UBERON:0003027	89.89	gold quality
left adrenal gland	UBERON:0001234	89.87	gold quality
anterior cingulate cortex	UBERON:0009835	89.69	gold quality
aorta	UBERON:0000947	89.40	gold quality
hindlimb stylopod muscle	UBERON:0004252	89.38	gold quality
left coronary artery	UBERON:0001626	89.33	gold quality
sperm	CL:0000019	89.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.17

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYC

miRNA regulators (miRDB)

13 targeting RAD51C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-493-5P	99.96	72.47	2382
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-95-5P	99.89	72.17	3973
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-548AG	99.77	69.25	1492
HSA-MIR-548AI	99.69	69.24	1494
HSA-MIR-548BA	99.69	69.14	1514
HSA-MIR-570-5P	99.69	69.24	1494
HSA-MIR-5003-5P	99.61	69.13	1624
HSA-MIR-5590-5P	98.81	68.78	969
HSA-MIR-6839-5P	96.74	68.29	1088
HSA-MIR-378J	96.44	66.20	1020

Functional genomics

ClinGen dosage: haploinsufficiency 3 (sufficient evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 82.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• This work describes the in vitro and in vivo identification of the RAD51B/RAD51C heterocomplex (PMID:11744692)
• Rad51B and Rad51C function through interactions with the human Rad51 recombinase and play a crucial role in the homologous recombinational repair pathway (PMID:12427746)
• analysis of protein domains important for functioning of RAD51L2; there is a specific requirement for RAD51L2 in gene conversion in mammalian cells (PMID:12966089)
• a fragment of Rad51B containing amino acid residues 1-75 interacts with the C-terminus and linker of Rad51C, residues 79-376, and this region of Rad51C also interacts with mRad51D and Xrcc3 (PMID:14704354)
• concluded that the RAD51 paralogs are involved in Holliday junction processing in human cells (PMID:14716019)
• cellular evidence for the function of human Rad51C in homologous recombinational repair (PMID:15292210)
• Rad51C plays an important role in regulating Rad51 degradation via the ubiquitin-mediated proteasome pathway. (PMID:16215984)
• RAD51C ensures a tight regulation of RAD51 assembly during DSB repair and plays a direct role in repairing DSBs in vivo. (PMID:16395335)
• the RAD51C-XRCC3-associated Holliday junction resolvase complex associates with crossovers and may play an essential role in the resolution of recombination intermediates prior to chromosome segregation (PMID:17114795)
• RAD51C is required for activation of the checkpoint kinase CHK2 and cell cycle arrest in response to DNA damage. (PMID:19451272)
• biallelic germline mutations in a RAD51 paralog are associated with an FA-like syndrome [case report] (PMID:20400963)
• Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene (PMID:20400964)
• Unable to confirm the contribution of the RAD51C gene to hereditary breast and ovarian cancer. (PMID:20697805)
• Data show there was no deleterious RAD51C mutation among the 454 familial breast/ovarian cancer patients. (PMID:20723205)
• Reports show RAD51C is a cancer susceptibility gene associated with increased risk of Fanconi anemia-like disorder, breast and ovarian cancer.[Review] (PMID:20952512)
• PALB2 mutations are present in a small but substantial proportion of inherited breast cancer cases, and indicates that RAD51C at a population level does not account for a substantial number of familial breast cancer cases (PMID:21409391)
• These results suggest RAD51C as the first moderate-to-high risk susceptibility gene for ovarian cancer. (PMID:21616938)
• RAD51C mutations are implicated in breast and ovarian cancer predisposition. (PMID:21750962)
• RAD51C is a rare breast and ovarian cancer susceptibility gene. (PMID:21980511)
• Missense variant of RAD51C (p.Gly264Ser) is a moderate penetrance allele in high-risk breast and ovarian cancer families. (PMID:21990120)
• unravel the critical role of RAD51C in the FA pathway of ICL repair and as a tumor suppressor. (PMID:22167183)
• RAD51C germline mutations in families with a history for both breast and ovarian cancer appear to have a low prevalence with the exception of some founder mutations. (PMID:22370629)
• study detected 1.3 percent mutations of RAD51C in breast and ovarian cancer families, while mutations in breast cancer only families seem to be very rare (PMID:22451500)
• RAD51C mutations are rare events among high-risk breast cancer and breast/ovarian cancer families. (PMID:22476429)
• RAD51C is a susceptibility gene for ovarian and BC. (PMID:22725699)
• the contribution of RAD51C and RAD51D gene mutations to an inherited high risk of ovarian cancer is very small (PMID:22752287)
• We propose that analogous to germline genetic mutations constitutive epimutations in BRCA1 and RAD51C may serve as the first hit of tumor development. (PMID:22843497)
• Study observed centrosome defects in the absence of XRCC3. While RAD51B and RAD51C act early in homologous recombination, XRCC3 functions jointly with GEN1 later in the pathway at the stage of Holliday junction resolution. (PMID:23108668)
• This study concludes that germline mutations in RAD51C contribute marginally to breast and ovarian cancer susceptibility in ethnically diverse, Jewish high risk families. (PMID:23117857)
• No RAD51C mutations c.837 + 1G > A or c.93delG were detected. (PMID:23176254)
• RAD51C-deficient cancer cells are highly sensitive to olaparib and offer preclinical proof-of-principle that RAD51C deficiency may be considered a biomarker for predicting the antitumor effects of olaparib. (PMID:23512992)
• The HsRAD51B-HsRAD51C complex plays a role in stabilizing the HsRAD51 nucleoprotein filament during the presynaptic phase of homologous recombination. (PMID:23810717)
• three different cancer susceptibility and FA proteins function in a DNA repair pathway based upon the PALB2 WD40 domain binding to RAD51C and BRCA2. (PMID:24141787)
• Paralogs of RAD51 might be candidates for genetic risk factors in sporadic squamous cell carcinomas of the head and neck. (PMID:24315737)
• Single nucleotide polymorphisms in the Rad51C gene are strongly associated with increased risk for developing head and neck cancer. (PMID:24631219)
• the Rad51C promoter fragment can be used to transcriptionally target cancer cells. (PMID:24742710)
• The findings suggest that RAD51C plays a marginal role in breast and ovarian cancer predisposition in Pakistan. (PMID:24800917)
• RAD51C mutation is associated with breast and ovarian cancer. (PMID:25086635)
• conclude that the woman has two potential disease-causing mutations and that predictive testing of family members should include both the RAD51C and BRCA2 mutation (PMID:25154786)
• Mutations in RAD51C are associated with drug resistance in breast cancer. (PMID:25292178)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	rad51c	ENSDARG00000068919
mus_musculus	Rad51c	ENSMUSG00000007646
rattus_norvegicus	Rad51c	ENSRNOG00000006661
drosophila_melanogaster	spn-D	FBGN0003482

Paralogs (6): RAD51 (ENSG00000051180), DMC1 (ENSG00000100206), XRCC3 (ENSG00000126215), RAD51B (ENSG00000182185), RAD51D (ENSG00000185379), XRCC2 (ENSG00000196584)

Protein

Protein identifiers

DNA repair protein RAD51 homolog 3 — O43502 (reviewed: O43502)

Alternative names: RAD51 homolog C, RAD51-like protein 2

All UniProt accessions (14): O43502, A0A087WZ35, A0A8V8TL64, A0A8V8TML3, A0A8V8TML8, A0A8V8TMU8, E9PI66, H7C1R0, H7C2Q5, J3QKK3, J3QLB5, J3QLQ2, J3QR58, Q7KZJ0

UniProt curated annotations — full annotation on UniProt →

Function. Essential for the homologous recombination (HR) pathway of DNA repair. Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Part of the RAD51 paralog protein complexes BCDX2 and CX3 which act at different stages of the BRCA1-BRCA2-dependent HR pathway. Upon DNA damage, BCDX2 seems to act downstream of BRCA2 recruitment and upstream of RAD51 recruitment; CX3 seems to act downstream of RAD51 recruitment; both complexes bind predominantly to the intersection of the four duplex arms of the Holliday junction (HJ) and to junction of replication forks. The BCDX2 complex was originally reported to bind single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA. The BCDX2 subcomplex RAD51B:RAD51C exhibits single-stranded DNA-dependent ATPase activity suggesting an involvement in early stages of the HR pathway. Involved in RAD51 foci formation in response to DNA damage suggesting an involvement in early stages of HR probably in the invasion step. Has an early function in DNA repair in facilitating phosphorylation of the checkpoint kinase CHEK2 and thereby transduction of the damage signal, leading to cell cycle arrest and HR activation. Participates in branch migration and HJ resolution and thus is important for processing HR intermediates late in the DNA repair process; the function may be linked to the CX3 complex. Part of a PALB2-scaffolded HR complex containing BRCA2 and which is thought to play a role in DNA repair by HR. Protects RAD51 from ubiquitin-mediated degradation that is enhanced following DNA damage. Plays a role in regulating mitochondrial DNA copy number under conditions of oxidative stress in the presence of RAD51 and XRCC3. Contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability. Involved in maintaining centrosome number in mitosis.

Subunit / interactions. Part of the RAD51 paralog protein complexes BCDX2 and CX3; the complexes have a ring-like structure arranged into a flat disc around a central channel. The BCDX2 complex consits of RAD51B, RAD51C, RAD51D and XRCC2; the CX3 complex consists of RAD51C and XRCC3. The BCDX2 subcomplex RAD51B:RAD51C interacts with RAD51. Interacts with SWSAP1; involved in homologous recombination repair. Interacts directly with PALB2 which may serve as a scaffold for a HR complex containing PALB2, BRCA2, RAD51C, RAD51 and XRCC3. Interacts with HELQ. Interacts with DNA damage up-regulated protein DDUP.

Subcellular location. Nucleus. Cytoplasm. Perinuclear region. Mitochondrion.

Tissue specificity. Expressed in a variety of tissues, with highest expression in testis, heart muscle, spleen and prostate.

Disease relevance. Fanconi anemia complementation group O (FANCO) [MIM:613390] A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. The disease is caused by variants affecting the gene represented in this entry. Breast-ovarian cancer, familial, 3 (BROVCA3) [MIM:613399] A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. The disease is caused by variants affecting the gene represented in this entry.

Induction. Stress-induced increase in the mitochondrial levels is seen.

Similarity. Belongs to the RecA family. RAD51 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
O43502-1	1	yes
O43502-2	2

RefSeq proteins (2): NP_002867, NP_478123* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013632	Rad51_C	Domain
IPR016467	DNA_recomb/repair_RecA-like	Family
IPR020588	RecA_ATP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR052093	HR_Repair_Mediator	Family

Pfam: PF08423

UniProt features (63 total): sequence variant 20, helix 17, strand 14, region of interest 2, mutagenesis site 2, turn 2, splice variant 2, chain 1, short sequence motif 1, binding site 1, modified residue 1

Structure

Experimental structures (PDB)

17 structures.

PDB	Method	Resolution (Å)
8OUZ	ELECTRON MICROSCOPY	2.2
8FAZ	ELECTRON MICROSCOPY	2.3
9SVY	ELECTRON MICROSCOPY	2.6
9Q29	ELECTRON MICROSCOPY	2.61
9Q2A	ELECTRON MICROSCOPY	2.67
9SVX	ELECTRON MICROSCOPY	2.7
9Q23	ELECTRON MICROSCOPY	2.84
9Q28	ELECTRON MICROSCOPY	2.84
9ZZR	ELECTRON MICROSCOPY	2.95
9SW0	ELECTRON MICROSCOPY	3
8GBJ	ELECTRON MICROSCOPY	3.11
9ON2	ELECTRON MICROSCOPY	3.16
9Q2B	ELECTRON MICROSCOPY	3.2
9Q25	ELECTRON MICROSCOPY	3.24
9OMY	ELECTRON MICROSCOPY	3.25
8OUY	ELECTRON MICROSCOPY	3.4
9OMZ	ELECTRON MICROSCOPY	3.51

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43502-F1	84.23	0.61

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 125–132

Post-translational modifications (1): 20

Mutagenesis-validated functional residues (2):

Position	Phenotype
131	significant loss of function; abolishes holliday junction resolution activity.
131	partial loss of function.

Function

Pathways and Gene Ontology

Reactome pathways

11 pathways

ID	Pathway
R-HSA-5685942	HDR through Homologous Recombination (HRR)
R-HSA-5693554	Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
R-HSA-5693568	Resolution of D-loop Structures through Holliday Junction Intermediates
R-HSA-5693579	Homologous DNA Pairing and Strand Exchange
R-HSA-5693616	Presynaptic phase of homologous DNA pairing and strand exchange
R-HSA-912446	Meiotic recombination
R-HSA-9701192	Defective homologous recombination repair (HRR) due to BRCA1 loss of function
R-HSA-9704331	Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
R-HSA-9704646	Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
R-HSA-9709603	Impaired BRCA2 binding to PALB2
R-HSA-983231	Factors involved in megakaryocyte development and platelet production

MSigDB gene sets: 553 (showing top): GOBP_DNA_TEMPLATED_DNA_REPLICATION_MAINTENANCE_OF_FIDELITY, ATF_B, REACTOME_MEIOTIC_RECOMBINATION, GOBP_CHROMOSOME_ORGANIZATION, GOMF_ENDONUCLEASE_ACTIVITY, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, YAGI_AML_WITH_INV_16_TRANSLOCATION, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOMF_NUCLEASE_ACTIVITY, CROONQUIST_NRAS_SIGNALING_DN, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_POSITIVE_REGULATION_OF_MITOTIC_CELL_CYCLE, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN

GO Biological Process (12): meiotic DNA recombinase assembly (GO:0000707), telomere maintenance via recombination (GO:0000722), double-strand break repair via homologous recombination (GO:0000724), DNA repair (GO:0006281), DNA recombination (GO:0006310), sister chromatid cohesion (GO:0007062), female meiosis sister chromatid cohesion (GO:0007066), reciprocal meiotic recombination (GO:0007131), male meiosis I (GO:0007141), spermatogenesis (GO:0007283), positive regulation of G2/M transition of mitotic cell cycle (GO:0010971), DNA damage response (GO:0006974)

GO Molecular Function (7): DNA binding (GO:0003677), ATP binding (GO:0005524), crossover junction DNA endonuclease activity (GO:0008821), ATP-dependent DNA damage sensor activity (GO:0140664), nucleotide binding (GO:0000166), four-way junction DNA binding (GO:0000400), protein binding (GO:0005515)

GO Cellular Component (10): nucleus (GO:0005634), nucleoplasm (GO:0005654), replication fork (GO:0005657), cytoplasm (GO:0005737), mitochondrion (GO:0005739), cytosol (GO:0005829), cell junction (GO:0030054), Rad51B-Rad51C-Rad51D-XRCC2 complex (GO:0033063), Rad51C-XRCC3 complex (GO:0033065), perinuclear region of cytoplasm (GO:0048471)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
Resolution of D-Loop Structures	2
Defective homologous recombination repair (HRR) due to PALB2 loss of function	2
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	1
HDR through Homologous Recombination (HRR)	1
Homologous DNA Pairing and Strand Exchange	1
Meiosis	1
Diseases of DNA Double-Strand Break Repair	1
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	1
Hemostasis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
cytoplasm	3
DNA metabolic process	2
meiosis I	2
male gamete generation	2
intracellular membrane-bounded organelle	2
DNA recombinase mediator complex	2
nuclear protein-containing complex	2
DNA recombinase assembly	1
meiosis I cell cycle process	1
telomere maintenance	1
mitotic recombination	1
recombinational repair	1
double-strand break repair	1
DNA damage response	1
cell cycle process	1
chromosome organization	1
meiotic sister chromatid cohesion	1
reciprocal homologous recombination	1
meiotic cell cycle process	1
male meiotic nuclear division	1
meiotic cell cycle	1
developmental process involved in reproduction	1
G2/M transition of mitotic cell cycle	1
regulation of G2/M transition of mitotic cell cycle	1
positive regulation of mitotic cell cycle phase transition	1
positive regulation of cell cycle G2/M phase transition	1
cellular response to stress	1
nucleic acid binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
DNA endonuclease activity, producing 3’-phosphomonoesters	1
ATP-dependent activity, acting on DNA	1
DNA damage sensor activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
DNA secondary structure binding	1
binding	1
nuclear lumen	1
chromosome	1

Protein interactions and networks

STRING

3178 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAD51C	K7EN88	K7EN88	999
RAD51C	PALB2	Q86YC2	996
RAD51C	RAD51D	O75771	992
RAD51C	XRCC3	O43542	991
RAD51C	XRCC2	O43543	989
RAD51C	RAD51B	O15315	988
RAD51C	BRCA2	P51587	976
RAD51C	BRCA1	P38398	954
RAD51C	RAD18	Q9NS91	942
RAD51C	FANCI	Q9NVI1	932
RAD51C	BARD1	Q99728	931
RAD51C	FANCD2	Q9BXW9	924
RAD51C	FANCL	Q9NW38	916
RAD51C	FANCG	O15287	909
RAD51C	FANCM	Q8IYD8	900

IntAct

89 interactions, top by confidence:

A	B	Type	Score
RAD51C	XRCC3	psi-mi:“MI:0915”(physical association)	0.940
RAD51C	RAD51B	psi-mi:“MI:0915”(physical association)	0.940
RAD51C	RAD51B	psi-mi:“MI:0914”(association)	0.940
RAD51B	RAD51C	psi-mi:“MI:0914”(association)	0.940
XRCC3	RAD51C	psi-mi:“MI:0914”(association)	0.940
XRCC3	RAD51C	psi-mi:“MI:0915”(physical association)	0.940
RAD51B	RAD51C	psi-mi:“MI:0915”(physical association)	0.940
RAD51D	RAD51C	psi-mi:“MI:0914”(association)	0.860
RAD51C	RAD51D	psi-mi:“MI:0915”(physical association)	0.860
RAD51D	RAD51C	psi-mi:“MI:0915”(physical association)	0.860
RAD51D	RAD51B	psi-mi:“MI:0914”(association)	0.850

BioGRID (129): RAD51C (Affinity Capture-MS), RAD51C (Affinity Capture-MS), RAD51C (Affinity Capture-MS), RAD51C (Affinity Capture-MS), RAD51C (Affinity Capture-MS), RAD51C (Affinity Capture-MS), RAD51C (Affinity Capture-MS), RAD51C (Affinity Capture-MS), RAD51C (Affinity Capture-MS), RAD51C (Two-hybrid), RAD51D (Two-hybrid), KLHL10 (Affinity Capture-MS), PTPN9 (Affinity Capture-MS), RAD51C (Affinity Capture-MS), CCDC140 (Affinity Capture-MS)

ESM2 similar proteins: A2AIG8, A6NFX1, O15315, O35083, O35719, O35790, O43502, O54783, O54804, O55229, O73884, P16442, P20417, P35790, P35821, P47802, Q01134, Q08DW9, Q27HK4, Q2TBS1, Q3T9M1, Q3U129, Q4R3I0, Q4R766, Q4R7M4, Q5E9H2, Q5E9T4, Q5SUV1, Q5SX19, Q5VYX0, Q6GV29, Q86XW9, Q8BVM4, Q8CIW5, Q8N2K0, Q8NBA8, Q8QGV6, Q8R2J9, Q8TCT0, Q924H5

Diamond homologs: A2SR54, A3CWU4, A3CXI2, A3MXX9, A4FWV5, A4WN87, A4YCN4, A5UMW0, A6VGG2, A8AB83, A9AA90, B0R636, B0R7Y4, B1YC14, B6YXT4, B8BM09, B8D610, C3MRI1, C3MY77, C3MZK6, C3N7M8, C3NFU5, C4KIT6, C5A2F7, C6A0N1, O27436, O28184, O29269, O35719, O42634, O43502, O57859, O58001, O73948, O74036, O77507, O93748, P0CW58, P0CW59, P0CW91

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
RAD51C	“form complex”	RAD51B/RAD51C	binding
RAD51C	“up-regulates activity”	XRCC3	relocalization

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 49 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	7	98.5×	5e-11
Impaired BRCA2 binding to PALB2	6	97.9×	1e-09
Homologous DNA Pairing and Strand Exchange	7	95.2×	5e-11
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	6	90.6×	1e-09
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	6	90.6×	1e-09
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	6	90.6×	1e-09
Resolution of D-loop Structures through Holliday Junction Intermediates	7	75.1×	2e-10
Presynaptic phase of homologous DNA pairing and strand exchange	5	48.5×	1e-06

GO biological processes:

GO term	Partners	Fold	FDR
double-strand break repair via homologous recombination	9	32.7×	2e-09

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

2222 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	203
Likely pathogenic	97
Uncertain significance	705
Likely benign	420
Benign	98

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1049265	NM_058216.3(RAD51C):c.966-2_1026+1del	Pathogenic
1069913	NM_058216.3(RAD51C):c.961C>T (p.Gln321Ter)	Pathogenic
1071025	NC_000017.10:g.(?56798097)(56801482_?)del	Pathogenic
1072950	NM_058216.3(RAD51C):c.401T>G (p.Leu134Ter)	Pathogenic
1073709	NM_058216.3(RAD51C):c.795del (p.Ala266fs)	Pathogenic
1074936	NC_000017.10:g.(?56780551)(56787357_?)del	Pathogenic
1076896	NC_000017.10:g.(?56769920)(56811662_?)del	Pathogenic
1098890	NM_058216.3(RAD51C):c.-13_14del (p.Met1_Thr5del)	Pathogenic
1098898	NM_058216.3(RAD51C):c.522_523insC (p.Ala175fs)	Pathogenic
1098902	NM_058216.3(RAD51C):c.635del (p.Arg212fs)	Pathogenic
1098904	NM_058216.3(RAD51C):c.672dup (p.Leu225fs)	Pathogenic
1098911	NM_058216.3(RAD51C):c.862del (p.Thr288fs)	Pathogenic
1098925	NM_058216.3(RAD51C):c.706_837+2del	Pathogenic
1171281	NM_058216.3(RAD51C):c.917del (p.Gly306fs)	Pathogenic
1177647	GRCh37/hg19 17q22(chr17:56809845-56811583)	Pathogenic
1177648	NM_058216.3:c.1_705del	Pathogenic
1177649	NM_058216.3(RAD51C):c.405_571del	Pathogenic
1177651	NM_058216.3:c.966_1027del	Pathogenic
1177654	c.706-4423_1131+7851del;p.(Val236_Leu376delins11)	Pathogenic
1209850	NM_058216.3(RAD51C):c.907G>T (p.Glu303Ter)	Pathogenic
1364557	NM_058216.3(RAD51C):c.915G>A (p.Trp305Ter)	Pathogenic
1365075	NM_058216.3(RAD51C):c.496del (p.Val166fs)	Pathogenic
1391838	NM_058216.3(RAD51C):c.981C>A (p.Tyr327Ter)	Pathogenic
140799	NM_058216.3(RAD51C):c.955C>T (p.Arg319Ter)	Pathogenic
141095	NM_058216.3(RAD51C):c.502A>T (p.Arg168Ter)	Pathogenic
1417564	NM_058216.3(RAD51C):c.491_492del (p.Phe164fs)	Pathogenic
141999	NM_058216.3(RAD51C):c.186_187del (p.Gln62fs)	Pathogenic
1425085	NM_058216.3(RAD51C):c.785_786insTTTTTTTTTTTTTTTTTTNNNNNNNNNNTCACCGTTTTAGCCGGGATGGTCTCGATCTCCTGACCTCGTGATCCGCCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCGGCCCGTACTCGGTTATT (p.Leu262delinsPhePhePhePhePhePheXaaXaaXaaXaaSerProPheTer)	Pathogenic
142544	NM_058216.3(RAD51C):c.158del (p.Ser53fs)	Pathogenic
142758	NM_058216.3(RAD51C):c.501_502dup (p.Arg168fs)	Pathogenic

SpliceAI

2373 predictions. Top by Δscore:

Variant	Effect	Δscore
17:58696691:A:AG	acceptor_gain	1.0000
17:58696692:G:GA	acceptor_gain	1.0000
17:58696692:GT:G	acceptor_gain	1.0000
17:58703194:A:AG	acceptor_gain	1.0000
17:58703195:G:GG	acceptor_gain	1.0000
17:58703325:CAAAG:C	donor_loss	1.0000
17:58703326:AAAG:A	donor_loss	1.0000
17:58703327:AAGG:A	donor_loss	1.0000
17:58703329:GG:G	donor_loss	1.0000
17:58703330:G:GC	donor_loss	1.0000
17:58703331:T:G	donor_loss	1.0000
17:58709854:TTTA:T	acceptor_loss	1.0000
17:58709856:TAG:T	acceptor_loss	1.0000
17:58709857:A:AG	acceptor_gain	1.0000
17:58709857:A:T	acceptor_loss	1.0000
17:58709858:G:GG	acceptor_gain	1.0000
17:58709986:TAGCT:T	donor_gain	1.0000
17:58709987:AGCT:A	donor_gain	1.0000
17:58709987:AGCTG:A	donor_loss	1.0000
17:58709988:GCT:G	donor_gain	1.0000
17:58709988:GCTG:G	donor_gain	1.0000
17:58709989:CT:C	donor_gain	1.0000
17:58709989:CTGT:C	donor_loss	1.0000
17:58709990:TG:T	donor_loss	1.0000
17:58709991:G:GG	donor_gain	1.0000
17:58709991:G:T	donor_loss	1.0000
17:58709992:T:G	donor_loss	1.0000
17:58709993:A:AC	donor_loss	1.0000
17:58709994:AG:A	donor_loss	1.0000
17:58709995:G:C	donor_loss	1.0000

AlphaMissense

2434 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:58724048:T:A	W305R	0.997
17:58724048:T:C	W305R	0.997
17:58695177:A:T	K131I	0.996
17:58724050:G:C	W305C	0.993
17:58724050:G:T	W305C	0.993
17:58696755:T:A	V156D	0.992
17:58724040:G:A	G302E	0.992
17:58724070:G:C	R312P	0.992
17:58732502:G:C	K328N	0.991
17:58732502:G:T	K328N	0.991
17:58695178:A:C	K131N	0.990
17:58695178:A:T	K131N	0.990
17:58709925:C:A	R258S	0.990
17:58720760:T:A	N284K	0.990
17:58720760:T:G	N284K	0.990
17:58724040:G:T	G302V	0.990
17:58709926:G:C	R258P	0.988
17:58695174:G:A	G130E	0.987
17:58695177:A:C	K131T	0.986
17:58695180:C:T	T132I	0.986
17:58709866:T:C	L238P	0.986
17:58720812:G:A	G302R	0.986
17:58720812:G:C	G302R	0.986
17:58695188:T:C	C135R	0.985
17:58703301:T:C	L226P	0.985
17:58695107:G:C	D108H	0.984
17:58695168:G:A	G128D	0.984
17:58695176:A:C	K131Q	0.984
17:58696763:G:C	D159H	0.984
17:58709869:T:A	V239E	0.984

dbSNP variants (sampled 300 via entrez): RS1000055579 (17:58698914 C>T), RS1000058826 (17:58732407 T>C), RS1000075342 (17:58705635 A>C), RS1000113630 (17:58692732 C>A,G,T), RS1000168479 (17:58690927 C>A,G,T), RS1000190110 (17:58716954 C>A), RS1000256213 (17:58710301 GA>G), RS1000380043 (17:58727787 T>G), RS1000383305 (17:58727982 C>T), RS1000392793 (17:58704761 G>A,T), RS1000563668 (17:58714284 C>G), RS1000588410 (17:58729487 T>C), RS1000593291 (17:58713967 T>G), RS1000779484 (17:58710508 A>AT), RS1000801570 (17:58707934 C>A,G,T)

Disease associations

OMIM: gene MIM:602774 | disease phenotypes: MIM:613390, MIM:613399, MIM:114480, MIM:613659, MIM:612555, MIM:167000, MIM:604370

GenCC curated gene-disease

Disease	Classification	Inheritance
RAD51C-related cancer predisposition	Definitive	Autosomal dominant
Fanconi anemia complementation group O	Strong	Autosomal recessive
breast-ovarian cancer, familial, susceptibility to, 3	Strong	Autosomal dominant
hereditary breast ovarian cancer syndrome	Supportive	Autosomal dominant
Fanconi anemia	Supportive	Autosomal recessive

ClinGen Gene-Disease Validity (2)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
RAD51C-related cancer predisposition	Definitive	AD
Fanconi anemia complementation group O	Limited	AR

Mondo (25): Fanconi anemia complementation group O (MONDO:0013248), hereditary neoplastic syndrome (MONDO:0015356), breast-ovarian cancer, familial, susceptibility to, 3 (MONDO:0013253), breast cancer (MONDO:0007254), hereditary breast ovarian cancer syndrome (MONDO:0003582), breast carcinoma (MONDO:0004989), uterine corpus cancer (MONDO:0006003), hereditary site-specific ovarian cancer syndrome (MONDO:0016249), RAD51C-related cancer predisposition (MONDO:0700273), familial ovarian cancer (MONDO:0016248), microcephaly (MONDO:0001149), long QT syndrome (MONDO:0002442), ovarian neoplasm (MONDO:0021068), hereditary breast carcinoma (MONDO:0016419), gastric cancer (MONDO:0001056)

Orphanet (8): Fanconi anemia (Orphanet:84), Inherited cancer-predisposing syndrome (Orphanet:140162), Hereditary breast and/or ovarian cancer syndrome (Orphanet:145), Hereditary breast cancer (Orphanet:227535), Rare ovarian cancer (Orphanet:213500), Hereditary site-specific ovarian cancer syndrome (Orphanet:213524), OBSOLETE: Familial ovarian cancer (Orphanet:213517), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

131 total (30 of 131 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000010	Recurrent urinary tract infections
HP:0000027	Azoospermia
HP:0000028	Cryptorchidism
HP:0000035	Abnormal testis morphology
HP:0000047	Hypospadias
HP:0000072	Hydroureter
HP:0000079	Abnormality of the urinary system
HP:0000083	Renal insufficiency
HP:0000107	Renal cyst
HP:0000126	Hydronephrosis
HP:0000130	Abnormality of the uterus
HP:0000135	Hypogonadism
HP:0000175	Cleft palate
HP:0000218	High palate
HP:0000238	Hydrocephalus
HP:0000252	Microcephaly
HP:0000268	Dolichocephaly
HP:0000286	Epicanthus
HP:0000316	Hypertelorism
HP:0000324	Facial asymmetry
HP:0000340	Sloping forehead
HP:0000347	Micrognathia
HP:0000364	Hearing abnormality
HP:0000365	Hearing impairment
HP:0000377	Abnormal pinna morphology
HP:0000453	Choanal atresia
HP:0000478	Abnormality of the eye
HP:0000483	Astigmatism
HP:0000486	Strabismus

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST002022_6	Testicular germ cell tumor	3.000000e-09
GCST002023_1	Testicular germ cell tumor	4.000000e-13
GCST002030_11	Primary tooth development (time to first tooth eruption)	2.000000e-09
GCST002774_29	Cognitive function	3.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004337	intelligence

MeSH disease descriptors (9)

Descriptor	Name	Tree numbers
D005199	Fanconi Anemia	C15.378.050.085.080.280; C15.378.190.223.500.500.280; C16.320.077.280; C18.452.284.280
D061325	Hereditary Breast and Ovarian Cancer Syndrome	C04.588.180.483; C04.588.322.455.431; C04.700.517; C12.050.351.500.056.630.705.431; C12.050.351.937.418.685.431; C12.100.250.056.630.705.431; C12.900.418.685.431; C16.320.700.517; C17.800.090.500.483; C19.344.410.431; C19.391.630.705.431
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547
D008594	Menopause, Premature	C12.050.351.500.056.630.250; C12.100.250.056.630.250; G08.686.157.500.500; G08.686.841.249.500.500
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D009386	Neoplastic Syndromes, Hereditary	C04.700; C16.320.700
D010051	Ovarian Neoplasms	C04.588.322.455; C12.050.351.500.056.630.705; C12.050.351.937.418.685; C12.100.250.056.630.705; C12.900.418.685; C19.344.410; C19.391.630.705
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750
C562840	Breast Cancer, Familial (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

72 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	6
Cisplatin	decreases expression, increases expression	3
Aflatoxin B1	increases expression	3
bisphenol A	affects expression, increases expression	2
Benzo(a)pyrene	increases expression	2
Doxorubicin	increases expression	2
Estradiol	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tretinoin	decreases expression, affects cotreatment, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Mitomycin	decreases expression, increases response to substance	2
Cadmium Chloride	decreases expression, increases expression	2
Copper Sulfate	decreases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
dicrotophos	decreases expression	1
alpha phellandrene	increases expression	1
beta-lapachone	decreases expression, increases expression	1
arsenite	affects binding, increases reaction	1
sodium bichromate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
cobaltous chloride	decreases expression	1
zinc chromate	affects localization	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine	increases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
2,3-dimethoxy-1,4-naphthoquinone	increases expression	1

Cellosaurus cell lines

4 cell lines: 2 cancer cell line, 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_VR80	U2OS#18-RAD51C-15	Cancer cell line	Female
CVCL_VR81	U2OS#18-RAD51C-15/C+	Cancer cell line	Female
CVCL_XX02	HEK293-DR-GFP-RAD51C-2	Transformed cell line	Female
CVCL_XX07	HEK293-DR-GFP-RAD51C-2/C+	Transformed cell line	Female

Clinical trials (associated diseases)

430 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02562170	PHASE4	COMPLETED	Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study
NCT00014638	PHASE4	COMPLETED	Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00022386	PHASE4	COMPLETED	Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00030758	PHASE4	UNKNOWN	Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
NCT00082277	PHASE4	COMPLETED	Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
NCT00087620	PHASE4	TERMINATED	A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
NCT00121836	PHASE4	COMPLETED	A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
NCT00126360	PHASE4	UNKNOWN	STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)
NCT00127933	PHASE4	COMPLETED	XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
NCT00128297	PHASE4	COMPLETED	Pamidronate Administration in Breast Cancer Patients With Bone Metastases
NCT00129597	PHASE4	UNKNOWN	Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy
NCT00131170	PHASE4	COMPLETED	Paravertebral Block for Breast Surgery
NCT00156039	PHASE4	COMPLETED	Randomized Trial of Follow-up Strategies in Breast Cancer
NCT00160901	PHASE4	COMPLETED	Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer
NCT00171847	PHASE4	TERMINATED	Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
NCT00176046	PHASE4	COMPLETED	Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study
NCT00190697	PHASE4	COMPLETED	A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
NCT00234195	PHASE4	COMPLETED	Wellbutrin XL, Major Depressive Disorder and Breast Cancer
NCT00237133	PHASE4	COMPLETED	Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women
NCT00237224	PHASE4	COMPLETED	Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole
NCT00241046	PHASE4	TERMINATED	Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00323479	PHASE4	COMPLETED	Arthralgia During Anastrozole Therapy for Breast Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00356148	PHASE4	COMPLETED	The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.
NCT00372476	PHASE4	COMPLETED	Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer
NCT00413491	PHASE4	UNKNOWN	National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations
NCT00484614	PHASE4	UNKNOWN	Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer
NCT00485953	PHASE4	COMPLETED	Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
NCT00496678	PHASE4	COMPLETED	Trial of Patient Navigation-Activation
NCT00531973	PHASE4	UNKNOWN	A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging
NCT00537771	PHASE4	COMPLETED	Liver Safety Under Upfront Arimidex vs Tamoxifen
NCT00544986	PHASE4	COMPLETED	A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
NCT00613275	PHASE4	COMPLETED	Patient Navigation in the Safety Net:CONNECTeDD
NCT00638599	PHASE4	COMPLETED	Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube in Modified Radical Mastectomy on Breast Cancer
NCT00647075	PHASE4	UNKNOWN	Yunzhi as Dietary Supplement in Breast Cancer
NCT00688909	PHASE4	COMPLETED	Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
NCT00699101	PHASE4	TERMINATED	Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy
NCT00742222	PHASE4	COMPLETED	Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer